The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Haas Jason since 2023.
This trader's CIK number is 1883821.
At the time of last reporting, Haas Jason was the Director of Ligand Pharmaceuticals Inc. (stock ticker symbol LGND).
Also see all insider trading activities at Ligand Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | SYRS | 100,000 | $161,217 | 137,803 | $28,938 | 34,208 | $0 |
| 2023 | SYRS | 0 | $0 | 0 | $0 | 2,000 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | LGND | 0 | $0 | 6,461 | $1,651,076 | 4,000 | $206,240 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | ODTX | 1,000 | $20,000 | 0 | $0 | 0 | $0 |
1. Syros Pharmaceuticals, Inc. (SYRS)
2. Ligand Pharmaceuticals Inc (LGND)
3. Odyssey Therapeutics, Inc. (ODTX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-18 | SYRS | Sale | 137,803 | .21 | 28,938 |
| 2024-10-31 | SYRS | Option Ex | 18,875 | .00 | 0 |
| 2024-09-10 | SYRS | Buy | 35,363 | 1.55 | 54,777 |
| 2024-09-11 | SYRS | Buy | 19,293 | 1.58 | 30,444 |
| 2024-09-12 | SYRS | Buy | 45,344 | 1.68 | 75,996 |
| 2024-03-31 | SYRS | Option Ex | 15,333 | .00 | 0 |
| 2023-03-31 | SYRS | Option Ex | 2,000 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-12 | LGND | Option Ex | 4,000 | 51.56 | 206,240 |
| 2026-06-12 | LGND | Sale | 6,461 | 255.54 | 1,651,076 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-05-08 | ODTX | Buy | 1,000 | 20.00 | 20,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Haas Jason (Director of Ligand Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.